Tandem off 20% as it loses insurer to Medtronic for insulin pumps

Perhaps not too surprisingly, medical device megagiant Medtronic ($MDT) has again bested tiny Tandem Diabetes Care ($TNDM) in the insulin pump market. Tandem disclosed that its customer UnitedHealthcare would adopt Medtronic as its in-network insulin pump provider.

Wall Street punished the small cap insulin pump player on the news--pushing its shares down by more than 20% in early trading. The change goes into effect as of July 1.

"This unexpected decision by UnitedHealthcare designates Medtronic as their preferred, in-network durable medical equipment provider of insulin pumps," Tandem said in a statement. "The company anticipates that this decision will prevent a majority of UnitedHealthcare members from purchasing an insulin pump on an in-network basis from Tandem Diabetes Care and several other durable medical equipment providers."

Tandem's t:slim G4 pump

About 1,200 of the 15,500 insulin pumps that Tandem sold last year were to people who would not now be eligible for in-network coverage under UnitedHealthcare. That's a significant portion of sales--roughly 8%.

Tandem markets its t:slim, t:slim G4 and t:flex insulin pumps. It sold 4,042 pumps during the first quarter and grew sales 63% to $20.1 million from the prior year's quarter. It had an operating loss of $19.2 million in the first quarter, only a bit below the $20.4 million in the first quarter of 2015.

"Having diabetes isn't a choice. How people manage it should be," summed up Tandem President and CEO Kim Blickenstaff in a statement on the UnitedHealthcare change. "Insulin pumps are not a one-size fits all solution. Selecting which pump is the best fit for a person to manage their therapy needs should be a decision made between a person and their healthcare provider."

Tandem first launched on the public markets in late 2013 with a $120 million IPO. It debuted with a $15 share price; now that hovers around $8.

- here is the announcement

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.